Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2011-08-16
2011-08-16
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S197110, C424S246100, C424S247100, C424S203100, C424S201100
Reexamination Certificate
active
07998487
ABSTRACT:
Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.
REFERENCES:
patent: 5932426 (1999-08-01), Baralle et al.
patent: 6171591 (2001-01-01), Hall
patent: 2003/0054010 (2003-03-01), Sebbel et al.
patent: 2003/0235818 (2003-12-01), Kathritch et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2005/0175588 (2005-08-01), Mosca
patent: 2005/0186621 (2005-08-01), Galarza et al.
patent: 2005/0214321 (2005-09-01), Rasochova et al.
Gubbins et al., “Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 ofBacillus anthracisprotective antigen.,” FEMS immunology and medical microbiology, vol. 47 No. 3, pp. 436-443 (Aug. 2006).
Zhang et al., “The 2β2-2β3 loop of anthrax protective antigen contains a dominant neutralizing epitope,” Biochemical and Biophysical Research Communications, vol. 341 No. 4, pp. 1164-1171.
Bradley et la. (2001) “Identification of the cellular receptor for anthrax toxin.”Nature, 414(6860): 225-229.
Buratti et al. (1669) “Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein.”Journal of Immunological Methods, 197: 7-18.
Fehr et al. (1998) “T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles.” PNAS, 95(16): 9477-9481.
Krishna et al. (2003) “Analysis of RNA packaging in wild-type and mosaic protein capsids of flock house virus using recombinant baculovirus vectors.”Virology, 305(1): 10-24.
Lacy et al. (2004) “Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor.” PNAS, 101(17): 6367-6372.
Manayani et al. (2007) “A Viral Nanoparticle with Dual Funtion as a Anthrax Antitoxin and Vaccine.”PloS Pathogens, 3(10): e142.
Ogasawara et al. (2006) “Recombinant Viral-like Particles of Parvivirus B19 as Antigen Carriers of Anthrax Protective Antigen.” In Vivo, 20: 319-324.
Schneemann et al. (1993) “Use of recombinant baculoviruses in synthesis of morphologically distinct viruslike particles of flock house virus, a nodavirus.”J. Virol. 67(5): 2756-2763.
Scobie et al. (2003) “Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.” PNAS, 100(9): 5170-5174.
Scobie et al. (2005) “A soluble receptor decoy protects rats against anthrax lethal toxin challenge.”J Infect Dis192(6): 1047-1051.
Scobie et al. (2006) “Anthrax toxin receptor 2-dependent lethal toxin killing in vivo.”PloS Pathlog2(10): e111.
Shivachandra et al. (2006) “In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient displays of large full-length proteins.”Virology, 345(1): 190-198.
Shivachandra et al. (2007) “Multicomponent anthrax toxin display and delivery using bacteriophage T4.”Vaccine, 25(7): 1225-1235.
Smallshaw et al.(2005) “Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin.”Vacine, 23: 4775-4784.
Venter et al. (2005) “Capsid protein synthesis from replicating RNA directs specific packaging of the genome of a multipartite, positive-strand RNA virus.”J. Virol, 79(10): 6239-6248.
Vitale et al. (2006) “Prophylaxis and therapy of inhalational anthrax y a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.”Infect Immun, 74(10): 5840-5847.
Wigelsworth et al. (2004) “Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen.”J Biol. Chem., 279(22): 23349-23356.
Dryden Kelly
Manayani Darly Joseph
Manchester Marianne
Marlett John M.
Rainey Godfrey Jonah Anderson
Littlepage Paul
Mosher Mary E
Quine Intellectual Property Law Group P.C.
The Salk Institute for Biological Studies
The Scripps Research Institute
LandOfFree
Antitoxin and vaccine platform based on nodavirus VLPs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitoxin and vaccine platform based on nodavirus VLPs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitoxin and vaccine platform based on nodavirus VLPs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674157